FAQ: Soligenix's ThermoVax Ebolavirus Vaccines Stability Data

What is the main topic of Soligenix’s recent announcement?

Soligenix announced the publication of new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax platform, with bivalent and trivalent vaccines retaining full potency after two years of storage at up to 40°C.

Why is this vaccine stability data significant?

This data is significant because ThermoVax enhances protein subunit vaccines by eliminating cold-chain requirements, improving global vaccine distribution and pandemic preparedness for dangerous viruses like Ebola and Marburg.

How does the ThermoVax platform work?

ThermoVax is a proprietary heat stabilization platform technology that formulates vaccines to maintain potency without refrigeration, allowing storage at temperatures up to 40°C (104°F) for extended periods.

What viruses are targeted by these vaccines?

The vaccines target Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens, with both bivalent and trivalent formulations showing stability and effectiveness.

Who developed these thermostable vaccines?

The vaccines were developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa and have demonstrated robust immune responses with up to 100% protection in non-human primate animal models.

Where can I find more detailed information about this research?

The full manuscript has been accepted by the journal Vaccine, and the complete press release is available at https://ibn.fm/kh3GE for more detailed information.

What are the practical benefits of eliminating cold-chain requirements?

Eliminating cold-chain requirements enables easier global distribution, reduces logistical costs, and improves accessibility in remote or resource-limited areas, enhancing pandemic preparedness worldwide.

What other vaccine programs does Soligenix have in development?

Soligenix’s Public Health Solutions segment includes RiVax for ricin toxin, filovirus vaccines for Marburg and Ebola, CiVax for COVID-19 prevention, all incorporating the ThermoVax platform technology.

How is this research funded?

This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

Where can investors find the latest updates about Soligenix?

The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX for investor information.